Leniolisib for Immune Dysregulation in CVID

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 12, 2025

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2026

Conditions
Common Variable Immunodeficiency (CVID)
Interventions
DRUG

Leniolisib

Planned dose will range from 10 mg twice daily to 70 mg twice daily

Trial Locations (6)

10029

RECRUITING

Mount Sinai Hospital, New York

20892

NOT_YET_RECRUITING

National Institute of Health, Bethesda

77030

RECRUITING

Texas Children's Hospital, Houston

80045

RECRUITING

Children's Hospital Colorado, Aurora

01805

RECRUITING

Lahey Hospital & Medical Center, Burlington

Unknown

RECRUITING

IIS La Fe, Valencia

Sponsors
All Listed Sponsors
collaborator

Lahey Hospital & Medical Center

OTHER

lead

Pharming Technologies B.V.

INDUSTRY

NCT06897358 - Leniolisib for Immune Dysregulation in CVID | Biotech Hunter | Biotech Hunter